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Background: Protection against infection by Newcastle disease virus (NDV), also designated as avian paramyxovirus
subtype-1 (APMV-1), is mediated by immune responses to the two surface glycoproteins, hemagglutinin-neuraminidase
(HN) and fusion (F) protein. Thus, a chimeric APMV-1 based vaccine that encodes APMV-8 HN- and F-proteins and
expresses the hemagglutinin of avian influenza virus (AIV) H5N1, is able to protect against HPAIV H5N1 but fails to
protect against NDV [PLoS One 8:e72530, 2013]. However, it is unclear whether avirulent APMV-subtypes, like
APMV-8 can induce subtype-specific immunity and protect from a homologous challenge.
Findings: APMV-8 infections of 3- and 6-weeks-old specific pathogen free (SPF)-chickens did not induce any
clinical signs but was associated with virus shedding for up to 6 days. Viral replication was only detected in
oropharyngeal- and never in cloacal swabs. Upon reinfection with homologous APMV-8, viral shedding was
restricted to day 2 and in contrast to naive SPF-chickens, only RNA but no infectious virus was recovered. No
protection was induced against virulent NDV challenge, although morbidity and mortality was delayed in APMV-8
primed chickens. This lack of protection is in line with a lack of reactivity of APMV-8 specific sera to APMV-1
HN-protein: Neither by hemagglutin-inhibition (HI) test nor immunoblot analyses, cross-reactivity was detected,
despite reactivity to internal proteins.
Conclusions: Immune responses mounted during asymptomatic APMV-8 infection limit secondary infection
against homologues reinfection and facilitates a delay in the onset of disease in a subtype independent manner
but is unable to protect against Newcastle disease, a heterologous APMV-subtype.
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Avian paramyxoviruses (APMV) replicate within the re-
spiratory tract and intestine of their natural avian host.
They belong to the genus Avulavirus in the family
Paramyxoviridae within the order Mononegavirales [1].
Currently, 12 subtypes have been identified with APMV-1
to −9 known as ‘classical strains’ [2] and APMV-10 to 12
recently described [3-5]. The prototypic virus, APMV-1 or
Newcastle Disease virus (NDV) causes a devastating dis-
ease in poultry and represents a major threat for poultry* Correspondence: christian.grund@fli.bund.de
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unless otherwise stated.production in the world. In contrast, the other APMV-
subtypes are not clinically relevant for poultry and circu-
late largely unnoticed in wild birds [6]. Also for APMV-1,
strains of low virulence are well known. They do not
induce clinical signs in immune competent birds but
confer protection against ND [7-9]. The generation of
recombinant NDV (rNDV) containing specific alterations
in the genome decreased residual virulence [10] and were
also used as vector system to express genes of other patho-
gens, e.g. highly pathogenic avian influenza virus (HPAIV)
[11,12]. To avoid interference by maternal NDV antibodies
with vaccine vector performance, we created a chimeric
virus (chNDVFHNPMV8H5) by substituting the envelope
glycoproteins hemagglutinin-neuraminidase (HN) andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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http://www.virologyj.com/content/11/1/179fusion protein (F) of NDV by those of APMV-8 and ex-
pressing H5 of HPAIV [13]. APMV-8 was chosen as donor
of HN and F because of its apathogenicity for poultry [14],
description of only weak cross-reactivity between APMV-1
and APMV-8 [15,16] and low prevalence [17-19]. Vac-
cination with this chimeric vector HPAIV-H5-vaccine
resulted in efficient protection against HPAIV H5N1
infection in chickens with NDV specific maternal anti-
bodies (MDA) [1]. However, evasion from maternal
NDV antibodies was accompanied by a lack of protec-
tion against ND. This observation corresponds to inves-
tigations by Nayak et al. [20] describing absence of
protection against NDV challenge after APMV-8
infection. The serological data of the vaccination exper-
iments with chNDVFHNPMV8H5 as well as the
APMV-8 infection suggested that APMV-8 glycoproteins
were immunogenic in the host. However, it remained un-
clear whether an APMV-8 immune response was sufficient
to induce protection against homologous APMV-8


















Figure 1 Oropharyngeal APMV-8 shedding. Shedding of APMV-8 was te
(B) old naive SPF-chickens or after reinfection (C) 3 weeks after priming. Bo
equivalents (IEQ) derived from a standard curve prepared for each PCR-run
RT-qPCR following a published protocol [11] with APMV-8 specific primer a
tested positive for infectious virus on LMH cells as described previously [22
by appropriate Wilcoxon-tests for paired and unpaired data respectively an
case of multiple testing. The global significance level was 0.05. All calculatiodemonstrating, that APMV-8 infection does not pre-
vent subsequent reinfection with homologous APMV-8
but limits viral shedding.
Materials and methods
Animal experiments
Chickens from SPF-eggs (LAH, Cuxhaven), hatched at
the FLI were infected oculo-nasally at 3 weeks of age
with 0.1 ml of APMV-8/goose/Delaware/1053/76 con-
taining 106 TCID50 (n = 18). Two days post infection
(dpi) two naive chickens were introduced as sentinel
birds. On each of day 2, 4, 6 and 21 dpi two inoculated
chickens were sacrificed and indicated internal organs
were tested for APMV-8 by RT-qPCR (primer probe se-
quence see Additional file 1: Table S1). Three weeks after
initial infection, groups were divided, one being challenged
oculo-nasally with NDV/Herts33/56 (106 EID50/animal)
and the other re-infected oculo-nasally with APMV-8/
goose/Delaware/1053/76 (106 TCID50/animal). In addition,
each of the two viruses at the same dose and route wasdpi/2dpi
B C
4 6 2 4 6
/6 2/6 6 0/7 0/7 0/7
sted at indicated days after infection of 3-weeks- (A) and 6-weeks-
xplots represent results of APMV-8 specific RT-qPCR with infectivity
. Testing for viral RNA was done by nucleocapsid protein (NP) specific
nd probes. Numbers indicate the number of animals per group that
]. Differences between time-points and groups were statistically tested
d labeled with specific symbols. Bonferroni correction was applied in


























Figure 2 Antibody response after APMV-8 infection. Serum
samples were taken at indicated time points after primary infection
of 3-weeks- (A) and 6-weeks- (B, control) old naive SPF-chickens or
after secondary APMV-8-infection (B, re-inf.), 3 weeks after priming.
Boxplots represent HI titers, numbers indicate the number of seropositive
animals per group (HI-titer >3).
Figure 3 Cross-reactivity of subtype specific immune sera with
APMV-1 proteins. Gradient purified APMV-1 strain Clone 30 were
lysed, and proteins were separated by SDS-PAGE, transferred on
nitrocellulose and probed by IgY-specific POD conjugated sera as
described previously [24]. Identity of proteins is indicated on the
right, molecular weights of marker proteins (PEQLAB™ prestained
protein marker IV) are indicated on the left. Lane 1–10 show results
of hyperimmune sera raised against APMV-1 (1), APMV-2 (2), APMV-3 /P
(3), APMV-3/T (4), APMV-4 (5), APMV-6 (6), APMV-7 (7), APMV-8 (8),
APMV-9 (9) and PPMV-1 (10), respectively. Sera from naive chickens did
not result in any band (data not shown).
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imals were scored daily according their clinical condition
(0 = healthy; 1 = sick; 2 = dead) and clinical index was cal-
culated analogous to determining intracerebral pathogen-
icity index (ICPI). At indicated time intervals post
infection either oropharyngeal and cloacal swabs (primary
infection) or combined oropharyngeal and cloacal swabs
were taken for virus detection. Heparinised blood samples
were obtained from all animals before vaccination, before
challenge- or reinfection as well as from all surviving birds
at the end of the observation period, and were tested
for NDV- and APMV-8-specific antibodies using the
hemagglutination inhibition (HI) assay [21]. All animal
experiments were carried out in BSL3 experimental
animal facilities and had been approved by the animal
welfare committee (LALLF M-V/TSD/7221.3-1.1-053/10).
See Additional file for specification of viruses (Additional
file 2: Table S2) and APMV-subtype specific sera with their
degree of cross-reactivity (Additional file 3: Table S3).
Results and discussion
APMV-8 infection
Primary APMV-8 infection was conducted in 3-weeks-
old SPF chickens by installation of 106 TCID50 of
APMV-8/goose/Delaware/1053/76 into the eye and nasal
cavity. Virus shedding was detected in oropharyngeal
swabs of all ten investigated animals on days 2 and 4 pi,
positive by RT-qPCR (Figure 1) as well as virus isolation.
Later, the amount of viral RNA declined and the number
of chickens shedding virus decreased to 8 and 1 on day
6 and 12, respectively. In these later swab samples, virus
isolation was not successful. Virus was never detected in
cloacal swabs, neither by RT-qPCR nor by virus isola-
tion. These results of confined virus replication paral-
leled the observation that virus RNA was not detected in
lung, liver, kidney or pancreas by RT-qPCR testing two
animals sacrificed on day 2, 4, 6 and 21 pi each. Viral
RNA was detected in the proventriculus of one chicken
on day 2 and 4 dpi (300 and 180 genome equivalents
(GEQ)/ml respectively) and in the duodenum on day 4
pi (160 GEQ/ml). Detection of a minute amounts RNA
in the upper digestive tract but never in feaces points to
degraded viral products rather than virus replication
within these organs. These data are in agreement with
observations by Kim et al. [14] detecting APMV-8 in tra-
chea but not lung, spleen or brain of three birds sampled
at day 4 after infection. Like in the former experiments,
all APMV-8 infected chickens remained healthy over the
entire observation period and developed like uninfected
hatch mates. However, virus replication was sufficient to
transmit APMV-8 to both sentinel chickens: Testing
serum 21 dpi, both sentinels had seroconverted.
All APMV-8-inoculated animals seroconverted within
the first week after infection and antibody titers rose toup to 8 (arithmetic mean Ø 6.9 ± 0.7) and 10 (Ø 8.6 ± 1.0)
log2 two and three weeks post infection, respectively
(Figure 2). Cross-reactivity of APMV-8 specific immune
sera to APMV-1 HN was neither observed by HI (data
not shown) nor immunoblot analyses (Figure 3).
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predominantly directed against internal virion proteins
(Figure 3; identification of proteins see Additional file 4:
Figure S1). Beside reactivity to the matrix (M) protein, a
protein band of about 50–55 kD was reproducibly de-
tected. Due to only minor differences in molecular
weight amongst NP, P and the F1 subunit of the F pro-
tein, further differentiation of antibody specificity was
not possible.
Three weeks after the initial experiment, five APMV-8
infected chickens and one sentinel animal, now six weeks
old, were reinfected with 106 TCID50 of homologous
APMV-8 strain. In addition, a group of six chickens from
the same hatch but kept separately, were APMV-8 in-
fected. As anticipated, birds inoculated with APMV-8 did
not develop clinical signs but virus shedding was detected
in naive 6-weeks-old chickens from day 2 pi by RT-qPCR
as well as by virus isolation comparable to shedding ob-
served before in the 3-weeks-old animals. In contrast, in
animals with previous exposure to APMV-8, virus was
only detected in 3 out of 6 (47, 89 and 12087 infectivity
equivalents/ml) inoculated chickens on day 2 pi and only
by RT-qPCR (Figure 3). The chickens that served as senti-
nel for the first infection remained virus negative in all
tested samples. After APMV-8 reinfection, a slight increase
in antibody titer was observed, supporting the notion of
limited virus-replication. It is interesting to note, that age
of the animal has apparently little effect on virus0 2 4
dpch






Figure 4 Course of NDV challenged chickens. Six-weeks-old naive SPF-c
age of 3 weeks (B) were challenged with virulent NDV Herts 33/56 and mo
shedding was tested by NDV-specific RT-qPCR 2 days pch (C) for SPF-chick
equivalents (GEQ) derived from a standard curve prepared for each PCR-run. D
Wilcoxon-tests for paired data. The global significance level was 0.05. All calculreplication, since virus shedding (Figure 3, A and B) and
antibody response (Figure 1, A and B control) in 3- and 6-
weeks-old chickens were comparable.
Heterologous NDV-challenge
APMV-8 preinfected (n = 6) and naive chickens (n = 6)
were challenged with NDV in parallel. All chickens suf-
fered severe clinical disease and swab samples tested
positive for virus on day 2 pch by APMV-1 specific RT-
qPCR [10] as well as by virus isolation (Figure 4). All
naive SPF-chickens became sick on day 2 and were dead
by day 3. In animals that had previously been infected
by APMV-8, the onset of disease was significantly de-
layed (p = 0.01515) with only one sick animal on day 2
pch and death of all chickens by day 5. Thus, clinical
index of the group with APMV-8 preinfection was lower
(1.36) compared to naive chickens (1.52) after NDV-
challenge (Figure 4). These data support the conclusion
that cross-reactivity between internal proteins has little
effect on the clinical outcome after a heterologous NDV
challenge, but is able to delay the clincal course. This is
in agreement with earlier experiments of Nayak and
colleagues [20]: They observed mortality up to day 11
in APMV-8 preinfected chickens, compared to 9 days
in non-immunized control chickens, and one out of five
chickens survived challenge with 200 chicken lethal
dose 50 (CLD50) of virulent NDV strain Texas-GB. It is in-


















hickens (A) or SPF-chickens infected/vaccinated with APMV-8 at the
nitored for clinical signs. Numbers indicate clinical index. Virus
ens (I) and APMV-8 vaccinated chickens (II). Given are genome
ifferences between groups were statistically tested by appropriate
ations were performed using R software [23], version 2.13.0(2011-04-13).
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a comparable delay of 2 days in the clinical course of ND
was observed applying the same NDV challenge model
[13]. Apparently, this effect of retarded clinical onset of
disease is independent of the subtype. Whether this effect
is associated to cross-reactivity to internal proteins needs
further elucidation.
Conclusions
Active local replication of APMV-8 induced an immune
response efficacious to limit APMV-8 reinfection but
unable to protect against heterologous APMV-1 subtype.
Additional files
Additional file 1: Table S1. Primers and probe for APMV-8 NP-specific
RT-qPCR.
Additional file 2: Table S2. Specification and source of viruses. 1
APMV-8 strain at the FLI was obtained in 1992 and working stocks for
sequencing and animal experiments were derived form the 5th and 6th
passage in SPF-chicken eggs. Genome was sequenced by Müller et al.
(Acc. Nr. FJ 619036). Compared to published sequences by Paldurai et al.
[25] (Acc. Nr. FJ 515863) 512 Single Nucleotide Polymorphism (SNP) are
evident compared to 21 SNP to pintail/Wakuya/20/78; FJ215864, [25].
Additional file 3: Table S3. Cross-reactivity of APMV-subtypes tested
by hemagglutination-inhibition test. Sera were produced by immunizing
six-week-old SPF chickens with beta propriolactone (0.05% v/v) inactivated
virus containing allantoic fluid emulsified with Freudschen adjuvant (Sigma).
Sera were taken two weeks after the last of three immunizations and stored
at −20°C. Results are given as log2 titer.
Additional file 4: Figure S1. Identification of specific APMV-1 proteins.
Gradient purified APMV-1 strain Clone 30 were lysed, and proteins were
separated by SDS-PAGE, transferred on nitrocellulose and probed by
IgY-specific POD-conjugated sera as described previously [24]. Identity of
proteins is indicated on the right, molecular weights of marker proteins
(PEQLAB™ prestained protein marker IV) are indicated on the left. Lanes
show results of chicken serum raised against PPMV-1 (1), monoclonal
antibodies directed against NP- (2), P- (3); HN-protein( 4) and monospecific
rabbit serum raised against F-protein (5).
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